Anifrolumab — Drug Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

5 Recruiting

5 Completed trials

5 Sponsors

17 Countries

Phase III

Phase II

Phase III: 6 Phase II/III: 1 Phase II: 3 Phase IV: 1

Oversight events:

2 serious breaches 1 corrective measure across 3 trials

View oversight register →

Indications tested

Systemic lupus erythematosus 3 Antiphospholipid syndrome 1 Polymyositis 1 Dermatomyositis 1 Cutaneous lupus erythematosus 1 Vitiligo 1

Sponsors using this IMP

AstraZeneca AB 7 Centre Hospitalier Universitaire De Bordeaux 1 Medical University Of Vienna 1 National And Kapodistrian University Of Athens 1 Universitair Medisch Centrum Groningen 1

All trials

11 total

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythema… Pending

2025-523670-17-00 Phase III 3 countries AstraZeneca AB
A Phase II Open-Label Pilot Trial Assessing the Safety of Anifrolumab in Adult Patients with Primary Antiphospholipid Syndrome (APS). … Recruiting

2025-520918-64-00 Phase II 1 country National And Kapodistrian University Of Athens
A study of anifrolumab in children and adolescents (5 to < 18 years old) with moderate to severe lupus to find the appropriate anifrolumab d… Recruiting

2022-502289-25-00 Phase III 6 countries AstraZeneca AB
The effect of anifrolumab on cutaneous lupus erythematosus characterized by the change of the inflammatory infiltrate analyzed by immunohist… Recruiting

2025-523133-26-00 Phase IV 1 country Medical University Of Vienna
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared … Recruiting

2023-504022-19-01 Phase III 13 countries AstraZeneca AB
Efficacy and tolerability of the combination of anifrolumab (300 mg IV) and phototherapy versus phototherapy in adults with progressive viti… Recruiting

2024-512041-17-00 Phase II 1 country Centre Hospitalier Universitaire De Bordeaux
A Phase III study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus Ended

2023-503692-24-00 Phase III 13 countries AstraZeneca AB
Determine effectiveness of Anifrolumab In Systemic sclerosis Ended

2023-505976-31-00 Phase III 10 countries Astrazeneca AB
Phase 3 Study of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis Ended

2023-506359-68-00 Phase III 8 countries Astrazeneca AB
Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus Ended

2024-513031-24-00 Phase II/III 5 countries AstraZeneca AB
ANISE-II; ANIfrolumab treatment for 24 weeks in patients with primary Sjögren’s syndrome – Efficacy and safety assessment in a randomized, d… Ended

2024-516770-29-00 Phase II 1 country Universitair Medisch Centrum Groningen

Showing 1–11 of 11 trials

← All drugs A–Z